Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

Feb 19, 2013 Full story:

Feb 19, 2013 - Gilead Sciences today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus infection who failed prior treatment.

Full Story

Bucharest, Romania

#1 Feb 19, 2013
Thank God, thank God and good doctors

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Health Discussions

Title Updated Last By Comments
Suisun council considers smoking ban at public ... 33 min N8 the Grrr8 6
Survey: Civilian Psychologists Struggle To Trea... 33 min HumanSpirit 3
African-American men, transgender women hit har... 43 min Beauty QUEEN 7
You could say this poll is smoking hot 54 min N8 the Grrr8 6
Few applying for insurance acknowledge smoking 1 hr N8 the Grrr8 2
Ban smoking in parks, report says 2 hr N8 the Grrr8 20
Angel Medical Center to Pay $85,000 to Settle E... 3 hr Interested Visitor 1
Pregnancy Symptoms - 12 Very Early Symptoms of ... (Jun '07) 7 hr Sheyla 5,991
The number of smokers has fallen to 19% of the ... 17 hr SMOKING MAIMS KILLS 1
A 25-year-old woman died in a private assessmen... 17 hr MERCK MAIMS KILLS 1
Flu vaccine less effective against mutant strain 17 hr MERCK MAIMS KILLS 1
Thanksgiving Blessings Found in Parenting an 'I... Mon VACCINES MAIM KILL 3

Health People Search

Addresses and phone numbers for FREE